Investing in euro high yield: Key considerations for insurers
KEY POINTS
Across European insurers’ portfolios, allocations to high-yield public corporate credit remain modest, at around just 2%.
This is unsurprising, as insurers naturally prioritise assets that align closely with their liability profiles. As a result, they tend to favour asset classes offering predictable cash flows, low default risk and low capital charges under Solvency II.
High yield, by contrast, is a market largely composed of mid-sized leveraged companies, often in transition, which therefore entails higher credit risk and greater volatility than its investment-grade counterpart.
This universe can also be broadened to include financial companies through senior or subordinated debt. Nevertheless, high yield can offer meaningful benefits to insurance portfolios, including:
• Higher credit spreads and therefore higher coupons with all-in yields supporting income objectives
• Diversification of the investable universe by expanding it beyond investment grade issuers
• Potentially greater resilience than other total return assets such as listed equities
The asset class also remains relatively liquid. When comparing the US’s older and larger market to Europe’s, average durations as of early 2026 are close, at around three years.
In terms of spread levels, both markets generally exhibit similar orders of magnitude (excluding the impact of foreign exchange hedging): around 290 basis points on average over the past year, despite the US market’s average rating being lower (BB/B+) at end of March 2026 than the euro market (BB/BB-).
Given the multifaceted nature of insurance balance sheets, any high-yield allocation needs to be assessed across several dimensions: economic efficiency with regards to a portfolio’s risk measured as volatility and with regards to required regulatory capital; accounting treatments; and sustainability considerations.
This paper reviews them in turn, focusing primarily on a euro strategy.
Disclaimer
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of BNP PARIBAS ASSET MANAGEMENT Europe or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.
Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ.
AXA IM and BNPP AM are progressively merging and streamlining our legal entities to create a unified structure
AXA Investment Managers joined BNP Paribas Group in July 2025. Following the merger of AXA Investment Managers Paris and BNP PARIBAS ASSET MANAGEMENT Europe and their respective holding companies on December 31, 2025, the combined company now operates under the BNP PARIBAS ASSET MANAGEMENT Europe name.